We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-3 of 3

Veracyte increases IPO target to $81 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 31 2013

South San Francisco-based Veracyte, Inc., which earlier this year completed a $28-million Series C financing round to expand and roll out its thyroid

Pharma and biotech stocks rise, M&A and IPO values strong, licensing deals

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Market analysts commenting on the dramatic rise in the Nasdaq Biotech Index (up 27) and the Dow Jones US Pharma Index (up 21) in the first half of

Biotech companies struggling in public markets

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand